Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women

Osteoporosis International

Volumn 20, Issue 2, 2009, Pages 283-290

  Langsetmo, L A ^a   Morin, S ^b   Richards, J B ^b,h   Davison, K S ^c   Olszynski, W P ^d   Prior, J C ^e   Josse, R ^f   Goltzman, D ^b,g  

^a CaMos National Coordinating Centre   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g ROYAL VICTORIA HOSPITAL   (Canada)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antiresorptive; Bisphosphonates; Fractures; Hormone replacement therapy; Nested case control study; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ESTROGEN; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; DENSITY; FEMALE; FOREARM FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIB FRACTURE; RISK; SAMPLING; SHOULDER FRACTURE; THERAPY EFFECT; VERTEBRA MALFORMATION; WRIST FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 58149469956     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0656-5     Document Type: Article

References (28)

1. P Sambrook C Cooper 2006 Osteoporosis Lancet 367 9527 2010 2018
2. O Johnell JA Kanis 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 12 1726 1733
3. ME Wiktorowicz R Goeree A Papaioannou JD Adachi E Papadimitropoulos 2001 Economic implications of hip fracture: health service use, institutional care and cost in Canada Osteoporos Int 12 4 271 278
4. A Cranney G Guyatt L Griffith G Wells P Tugwell C Rosen 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 4 570 578
5. JE Rossouw GL Anderson RL Prentice 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 3 321 333
6. ST Harris NB Watts HK Genant 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 14 1344 1352
7. DM Black DE Thompson DC Bauer 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 11 4118 4124
8. NB Watts K Worley A Solis J Doyle R Sheer 2004 Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database J Manag Care Pharm 10 2 142 151
9. SL Silverman NB Watts PD Delmas JL Lange R Lindsay 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 1 25 34
10. TP van Staa L Abenhaim C Cooper 1998 Use of cyclical etidronate and prevention of non-vertebral fractures Br J Rheumatol 37 1 87 94
11. N Kreiger A Tenenhouse L Joseph 1999 Research notes: the Canadian Multicentre Osteoporosis Study (CaMos)-background, rationale, methods Can J Aging 18 376 387
12. Rothman K (2002) Epidemiology: an Introduction. Oxford University Press, New York
13. JA Kanis A Oden O Johnell B Jonsson LC de Laet A Dawson 2001 The burden of osteoporotic fractures: a method for setting intervention thresholds Osteoporos Int 12 5 417 427
14. SA Jackson A Tenenhouse L Robertson 2000 Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos) Osteoporos Int 11 8 680 687
15. BR Shah A Laupacis JE Hux PC Austin 2005 Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review J Clin Epidemiol 58 6 550 559
16. S Boonen MR McClung R Eastell FG El-Hajj IP Barton P Delmas 2004 Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old J Am Geriatr Soc 52 11 1832 1839
17. SR Cummings DM Black DE Thompson 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 24 2077 2082
18. SJ Whiting TJ Green MS Calvo 2007 Vitamin D intakes in North America and Asia-Pacific countries are not sufficient to prevent vitamin D insufficiency J Steroid Biochem Mol Biol 103 3-5 626 630
19. D Rucker JA Allan GH Fick DA Hanley 2002 Vitamin D insufficiency in a population of healthy western Canadians CMAJ 166 12 1517 1524
20. GA Heckman A Papaioannou RJ Sebaldt 2002 Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates BMC Musculoskelet Disord 3 6
21. JP Brown RG Josse 2002 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 167 10 Suppl S1 S34
22. SR Majumdar FA McAlister CD Furberg 2004 From knowledge to practice in chronic cardiovascular disease: a long and winding road J Am Coll Cardiol 43 10 1738 1742
23. A Papaioannou L Giangregorio B Kvern P Boulos G Ioannidis JD Adachi 2004 The osteoporosis care gap in Canada BMC Musculoskelet Disord 5 11
24. L Giangregorio A Papaioannou A Cranney N Zytaruk JD Adachi 2006 Fragility fractures and the osteoporosis care gap: an international phenomenon Semin Arthritis Rheum 35 5 293 305
25. RB D'Agostino Jr RB D'Agostino Sr 2007 Estimating treatment effects using observational data JAMA 297 3 314 316
26. K Benson AJ Hartz 2000 A comparison of observational studies and randomized, controlled trials N Engl J Med 342 25 1878 1886
27. DM Black AV Schwartz KE Ensrud 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 24 2927 2938
28. SL Greenspan RD Emkey HG Bone 2002 Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 137 11 875 883